ACC Results Recap Part II: CardioMEMS Post-Approval Trial Shows Monitoring Reduces Heart-Failure Hospitalizations; Medtronic’s Tyrx Envelope Reduces Infections
Executive Summary
Medtech Insight's Results Recap is a regular feature covering the major device trial results compiled by MedDeviceTracker. This is the second of three Results Recaps covering trial data presented at the American College of Cardiology Scientific Sessions in New Orleans, March 16-18, including clinical trial data on devices from Abbott Laboratories, Medtronic, Medi-Lynx, and iRhythm. See Part 1 of our ACC Results Recap for more on the groundbreaking trials of transcatheter aortic valve replacement in low-risk patients and the Apple Heart study of Apple Watch's ability to track atrial fibrillation.
You may also be interested in...
Medtronic’s Anti-Bacterial Implantable Device Envelope Proves Cost-Effective In Study
A new analysis of the WRAP IT study shows the Tyrx absorbable antibacterial envelope is a cost-effective tool for preventing infections around cardiac implantable electronic devices.
Abbott Launches New App To Keep Heart Failure Patients Out Of The Hospital
The Merlin 10.0 update to Abbott’s its Merlin patient care network, which works with the CardioMEMS HF sensor system, allows physicians to communicate directly with patients.
Verily And iRhythm Agree To Collaborate On Atrial Fibrillation
Verily Life Sciences and iRhythm Technologies have agreed to co-develop technology for screening, diagnosing and managing patients with atrial fibrillation, combining iRhythm’s artificial intelligence system for diagnosing arrhythmias with Verily’s health data analytics technology.